Clinical Study

Primary Biliary Cholangitis (Pbc) Clinical Trial

Posted Date: Oct 7, 2021

  • Investigator: Kenneth Sherman
  • Specialties: Gastroenterology, Liver Disease
  • Type of Study: Drug

TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness


Eligible Patients Must Have A Diagnosis Of Pbc.


Pbc, Cirrhosis, Fibrosis

For More Information:

Liz Stambrook

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.